Details for New Drug Application (NDA): 083770
✉ Email this page to a colleague
NDA 083770 describes HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE, which is a drug marketed by Watson Labs and is included in one NDA. Additional details are available on the HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE profile page.
The generic ingredient in HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE is hydralazine hydrochloride; hydrochlorothiazide; reserpine. There are twenty-one drug master file entries for this compound. Additional details are available on the hydralazine hydrochloride; hydrochlorothiazide; reserpine profile page.
The generic ingredient in HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE is hydralazine hydrochloride; hydrochlorothiazide; reserpine. There are twenty-one drug master file entries for this compound. Additional details are available on the hydralazine hydrochloride; hydrochlorothiazide; reserpine profile page.
Summary for 083770
| Tradename: | HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE |
| Applicant: | Watson Labs |
| Ingredient: | hydralazine hydrochloride; hydrochlorothiazide; reserpine |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 25MG;15MG;0.1MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
